EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma – a retrospective study

Caroline Glatzel, Inga Hansen-Abeck iD, Nina Booken, Johannes Düll, Matthias Goebeler iD, Patrick Schummer iD, Marion Wobser iD

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025

DOI: 10.1111/ddg.15826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Caroline Glatzel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Skin Neoplasms, Brentuximab Vedotin, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cutaneous peripheral T cell lymphomas (PTCL) are rare and show an aggressive course with limited response to therapy. The efficacy of brentuximab vedotin in cutaneous peripheral T cell lymphomas has not yet been systematically investigated. Patients and methods In this retrospective analysis, we evaluated brentuximab vedotin as monotherapy or in combination therapy in patients with cutaneous CD30‐positive peripheral T cell lymphoma (n = 9).

Results

Overall, the therapy showed good efficacy and acceptable tolerability. One patient achieved an almost complete response, five had a partial response, and two had a mixed response as best overall response. The median time to response was 31.5 days (interquartile range 12–53). The median duration of response was short at 4.3 months. Median overall survival from initiation of brentuximab vedotin was 15.2 months; four of nine patients died from advanced lymphoma and one patient died from an unrelated cause.

Conclusion

Brentuximab vedotin as monotherapy or combination therapy is a rapidly effective and tolerable treatment option for patients with cutaneous PTCL, although the duration of response is short.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, CutaneousSkin NeoplasmsBrentuximab VedotinAntineoplastic Agents, ImmunologicalLymphoma, T-Cell, PeripheralRetrospective StudiesHumansAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeTime FactorsMaleFemaleAdultMiddle AgedAgedKi-1 Antigen

Stichwörter der Autor:innen

Cutaneous peripheral T cell lymphomas (PTCL)brentuximab vedotinbrentuximab vedotin mono‐ and combination therapycutaneous CD30‐positive peripheral T cell lymphomas

Substanzen

Brentuximab VedotinAntineoplastic Agents, ImmunologicalKi-1 Antigen

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
  • Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Internal Medicine II, Würzburg University Hospital, University of Würzburg, Würzburg, Germany.

ORCID-Profile: Inga Hansen-Abeck, Matthias Goebeler, Patrick Schummer, Marion Wobser

Zitieren

APA

Glatzel, C., Hansen-Abeck, I., Booken, N., Düll, J., Goebeler, M., Schummer, P., & Wobser, M. (2025). Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma – a retrospective study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15826

Vancouver

Glatzel C, Hansen-Abeck I, Booken N, Düll J, Goebeler M, Schummer P, et al. Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma – a retrospective study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15826

BibTeX
@article{Glatzel2025,
  author = {Glatzel, Caroline and Hansen-Abeck, Inga and Booken, Nina and Düll, Johannes and Goebeler, Matthias and Schummer, Patrick and Wobser, Marion},
  title = {Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma – a retrospective study},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2025},
  doi = {10.1111/ddg.15826}
}
Kostenlos starten →